According to CEO Mickael Ghossein, the company will continue to expand its healthcare offering across more territories, particularly in emerging markets.
Orange which partnered with mPedigree, a Ghanaian startup, in 2012, has been enabling the fight against counterfeit drugs in the continent as statistics indicate close to 30 per cent of all malaria drugs on chemist’s shelves are fake.
Under the Orange Healthcare scheme Ghossein said his company would also strengthen traditional healthcare systems practiced in various parts of Kenya, as well as the modernisation and equipping of various facilities.
“Through Orange Healthcare, we want to improve traditional healthcare systems to the benefit of the whole population. Currently, we’re helping to modernise the healthcare infrastructure as well as healthcare systems as a whole and also equip healthcare facilities with communications solutions,” said Ghossein.
He added the company’s partnership with mPedigree had offered much needed e-solutions to countering the counterfeit drugs menace, with the company’s 2.5 million customers able to access the service while using Flutrox (an antifungal drug) and Knac (an inflammatory analgesic or painkiller).
“The partnership with mPedigree in Kenya is part of an ongoing strategic move that will see Orange launch a number of e-solutions designed to respond to market needs and offer greater convenience to customers. We are convinced that the medicine of tomorrow is a connected medicine in which the management of healthcare data and medical information play an essential role,” he said.
Orange is also in partnership with Mali’s Mobile Santé, used to track epidemiological data, Senegal’s computerized management of payments between healthcare professionals and supplemental insurance companies as well as other innovations in Egypt and Ivory Coast.